Great Lakes Retirement Inc. Has $870,000 Stake in Becton, Dickinson and Company $BDX

Great Lakes Retirement Inc. raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 10.6% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 5,049 shares of the medical instruments supplier’s stock after purchasing an additional 483 shares during the period. Great Lakes Retirement Inc.’s holdings in Becton, Dickinson and Company were worth $870,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Saudi Central Bank acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at about $26,000. Cornerstone Planning Group LLC lifted its position in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 99 shares in the last quarter. Kelly Lawrence W & Associates Inc. CA bought a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $31,000. Bank of Jackson Hole Trust lifted its position in shares of Becton, Dickinson and Company by 85.6% during the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 95 shares in the last quarter. Finally, WPG Advisers LLC bought a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $36,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.3%

NYSE:BDX opened at $178.77 on Friday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $51.24 billion, a PE ratio of 32.15, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. The firm’s 50 day moving average is $188.38 and its 200 day moving average is $183.04. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion for the quarter. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 1,895 shares of company stock worth $358,995. Insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on BDX. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Royal Bank Of Canada reissued a “sector perform” rating and set a $211.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Morgan Stanley lifted their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Argus lifted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.